VCYTVeracyte, Inc.
$45.23+33% 1Y
$45.23
$30.0152 weeks$59.55
The financials
Veracyte, Inc. by the numbers
Veracyte, Inc. (VCYT) reported revenue of $150M in Q2 2026 (quarter ended Jun 30, 2026), up 15% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $25M (17% of revenue). For the full year FY2025, revenue was $517M (+16% year on year) and net income $66M. Its largest product in Q2 2026 was Testing at $146M, 96% of the disclosed total, well ahead of Testing Other at 3.0%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $150M | $130M | +15% |
| Gross profit | $109M | $90M | +21% |
| Operating income | $23M | −$5.3M | to a profit |
| Net income | $25M | −$980K | to a profit |
| Diluted EPS | $0.31 | −$0.01 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Testing | $146M | 96% |
| Testing Other | $4.5M | 3.0% |
| Biopharmaceutical And Other Biopharmaceutical | $802K | 0.5% |
| Biopharmaceutical And Other | $802K | 0.5% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $151.8M (+8.5%)
Testing Other grew +150% year on yearBiopharmaceutical And Other Contract Manufacturing And Testing -100% year on year
Segment Latestquarter on quarteryear on year
- Testing$145.7M$145.7Mquarter on quarter +7.8%year on year +19%+7.8%+19%
- Testing Other$4.5M$4.5Mquarter on quarter +7.1%year on year +150%+7.1%+150%
- Biopharmaceutical And Other Biopharmaceutical$802.0K$802.0Kquarter on quarter +166%year on year -70%+166%-70%
- Biopharmaceutical And Other$802.0K$802.0Kquarter on quarter +166%year on year -81%+166%-81%
- Biopharmaceutical And Other Contract Manufacturing And Testing$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
On our screens:Most shorted stocks
Diagnostics & Research
Ranks #8 of 21 by RyuScore